Iga Nephropathy Clinical Trials
Here are the 6 most popular medical studies for iga nephropathy
Felzartamab for IgA Nephropathy
This trial is testing a new drug for IgA Nephropathy, a kidney disease. The trial is comparing the new drug to a placebo, and is double-blind, meaning neither the patients nor the researchers know who is receiving which treatment.
Immunoglobulin A Nephropathy Clinical Trials
View 10 Immunoglobulin A Nephropathy medical studies.
IgAN Clinical Trials
View 10 IgAN medical studies.
Phase 3 Iga Nephropathy Clinical Trials
View 22 phase 3 iga nephropathy medical studies.
Iga Nephropathy Clinical Trials With No Placebo
View 22 iga nephropathy medical studies that do not have a placebo group.
Povetacicept for Kidney Disease
This trial will assess if a drug (povetacicept) is safe & potentially beneficial in treating IgA nephropathy, membranous nephropathy & lupus nephritis. Participants receive drug every 4 weeks for 6 months, with the possibility of a 6-month extension.
Frequently Asked Questions
Introduction to iga nephropathy
What are the top hospitals conducting iga nephropathy research?
When it comes to the advancement of medical knowledge and treatment options for IgA nephropathy, there are several hospitals leading the way. Amicis Research Center in Northridge is currently conducting three active clinical trials focused on this condition, showing their commitment to finding new solutions for patients. Interestingly, despite being a relatively new area of research, Amicis Research Center has notched up zero all-time trials in IgA nephropathy—highlighting the importance of ongoing studies in this field. Similarly dedicated to exploring innovative approaches is Kidney Disease Medical Group in Glendale with two ongoing clinical trials specifically targeting IgA nephropathy.
Heading eastward to Denver, Colorado Kidney Care stands out as another prominent institution actively contributing to advancements in understanding and treating IgA nephropathy with two current clinical trials underway. This demonstrates their dedication towards improving patient outcomes through cutting-edge research. Meanwhile, New York, Colorado Kidney Care stands out as another prominent institution actively contributing to advancements in understanding and treating IgA nephropathy with two current clinical trials underway. This demonstrates their dedication towards improving patient outcomes through cutting-edge research. Meanwhile, New York Nephrology located in Clifton Park also takes part by hosting two active iga nephropathy investigations; proof that even smaller facilities can make significant impacts on scientific progress within specialized areas.
Last but not least is Academic Medical Research Institute based in Los Angeles where researchers are diligently working on discovering breakthroughs for IgA nephropathy through their own set of two active clinical examinations at present moment.These collective efforts from different locations across the country showcase a united front against this kidney disorder which ultimately affects thousands worldwide.Their endeavor encompasses both well-established institutions and smaller-scale centers paving paths towards better understanding and improved treatments for individuals diagnosed with IgA nephropathy—a testament that progress knows no boundaries when it comes to enhancing healthcare outcomes
Which are the best cities for iga nephropathy clinical trials?
In the realm of IgA nephropathy clinical trials, several cities emerge as frontrunners for research and innovation. Los Angeles, California leads the pack with 11 active trials investigating treatments like Telitacicept 240mg, Atrasentan, and BION-1301. El Paso, Texas follows closely behind with 6 ongoing studies examining interventions such as Telitacicept 240mg and Felzartamab. Northridge, California also boasts 6 active trials focusing on Telitacicept 240mg and BION-1301 among other potential therapies. Lastly, Dallas and Houston in Texas both offer individuals battling IgA nephropathy access to a considerable number of active trials exploring various treatments including Atacicept, sparsentan, and BION-1301 Multiple Doses. These cities serve as critical hubs for advancing knowledge and improving care options for those affected by this condition.
Which are the top treatments for iga nephropathy being explored in clinical trials?
Clinical trials are shedding light on the most promising treatments for IgA nephropathy. Among these, some notable contenders include:
- Budesonide: Currently being investigated in three active clinical trials.
- Rituximab: Garnering attention with two ongoing trials focused on its effectiveness against IgA nephropathy.
- Olokizumab: Showing promise in early-stage research, with one trial currently exploring its potential benefits for patients. These treatments offer hope and hold significant potential for improving outcomes for individuals living with IgA nephropathy.
What are the most recent clinical trials for iga nephropathy?
Recent clinical trials offer hope for individuals with IgA nephropathy, a condition characterized by inflammation in the kidneys. Among these trials is Sequence BA, which is currently in Phase 2 and became available on 7/20/2023. Additionally, BION-1301 has entered Phase 3 as a potential treatment option for IgA nephropathy since becoming available on 6/27/2023. Similarly, Atacicept has also progressed to Phase 3 after its availability on 5/23/2023. These advancements demonstrate ongoing efforts to develop effective interventions that can improve the lives of those affected by this kidney disorder.
What iga nephropathy clinical trials were recently completed?
Recently concluded clinical trials have made significant strides in better understanding and treating IgA nephropathy. Notably, a trial sponsored by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) was completed in November 2021. This study delved into new therapeutic approaches for IgA nephropathy, shedding light on potential advancements in managing this complex kidney disorder. The completion of this trial highlights the ongoing commitment to research that aims to improve outcomes for individuals affected by IgA nephropathy.